Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
The collaboration between the chipmaker and Abridge, a developer of generative AI for healthcare, will involve data-sharing to improve Nvidia’s general-purpose models, which in turn will be used to make Abridge’s clinical offerings more efficient.
The Kentucky-based insurance giant had owned a 40% stake in the hospice company, stemming from its 2021 acquisition of Kindred Healthcare. Humana said a “consortium of investors" is making the buy, but few details were revealed.
The buyout, announced last summer, drew the attention of federal regulators at the Federal Trade Commission, concerned that competition for ambulatory surgery services would be stifled by the merger. To appease the agency, Ascension has agreed to divest from some centers previously owned by Amsurg.
When Mayo Clinic and Microsoft announced last week that they’re partnering to develop a frontier AI model for healthcare, observers could see where Mayo’s expertise in advanced digital medicine would interest Microsoft. The Big Tech behemoth has not been coy about its healthcare ambitions.
Citing two sources familiar with the matter, journalists at CBS News said the health system is suspected of violating the Foreign Corrupt Practices Act. No charges have been filed.
When it comes to adopting healthcare AI, large, well-off hospitals are likely to frequently homer while smaller, struggling institutions go down looking. (Baseball analogy in honor of tonight’s Midsummer Classic.)
Morphic's new treatment for inflammatory bowel disease is in Phase II clinical trials and shows promise in improving patient outcomes. Eli Lilly will purchase the company for $57 per share in cash.